An Epidermal Microfluidic Screening Panel for Diabetes Mellitus Related Disorders

糖尿病（DM）是一种常见的、多方面的疾病，影响着全世界大量的个体。2型糖尿病（T2D）约占患者总数的90%，并与大量不良健康结果相关，最重要的长期糖尿病相关疾病包括慢性肾病（CKD）、心血管疾病、神经病变和急性疾病（如酮症酸中毒）。缺乏对dm相关合并症发病的便捷诊断工具，特别是CKD和酮症酸中毒，给干预和治疗带来了限制。虽然已经提出了多种生物分子和生物物理标记物用于DKD、酮症酸中毒和神经病变，但目前还没有标准化的方法或仪器。迫切需要改进测量方法，以便在家庭环境中评估糖尿病相关病理，就像目前监测血糖一样容易。

Diabetes Mellitus (DM) is a common, multifaceted condition affecting a vast number of individuals worldwide. Type-2 DM (T2D) comprises an estimated 90% of the patient population and is associated with substantial adverse health outcomes with the most important long-term DM-related disorders comprising chronic kidney disease (CKD), cardiovascular disease, and neuropathy and acute conditions such as ketoacidosis. The lack of facile diagnostic tools for the onset of DM-related comorbidities, particularly CKD and ketoacidosis, imposes intervention and treatment limitations. Although multiple biomolecular and biophysical markers have been proposed for DKD, ketoacidosis, and neuropathy, no standardized method or instrumentation currently exists. There is a critical need for improved measurement methods that will evaluate diabetes associated pathology in the home setting as easily as glucose is presently monitored. Here, the proposed work will develop a novel wearable system that integrates analysis of biochemical markers from eccrine sweat and biophysical activity sensing to establish a DM-relevant screening panel. Sweat contains a wealth of biomarkers relevant to health status, including electrolytes, metabolites, organic compounds, inflammatory/stress biomarkers, proteins and hormones. Aspects of sweat rate and composition have been used in assessing cystic fibrosis, drug use, physical fatigue, cognitive state, depression, and hypertension, among other conditions. This fully-integrated system represents a significant step towards improving the clinical assessment of the onset of DM-relevant complications and disease progression. The platform will house multi-use flexible electronics and a network of underlying microfluidic channels and biochemical assays for non-invasive collection and analysis of key sweat biomarkers. The microfluidics portion is a single use substrate that will have onboard colorimetric and electrochemical assays corresponding to identified bioanalytes for real-time analysis. The key biophysical and biochemical parameters monitored correspond to promising indicators of disease states for DKD, ketoacidosis, or neuropathy.